MA35717B1 - Preparation a liberation prolongee - Google Patents

Preparation a liberation prolongee

Info

Publication number
MA35717B1
MA35717B1 MA37034A MA37034A MA35717B1 MA 35717 B1 MA35717 B1 MA 35717B1 MA 37034 A MA37034 A MA 37034A MA 37034 A MA37034 A MA 37034A MA 35717 B1 MA35717 B1 MA 35717B1
Authority
MA
Morocco
Prior art keywords
pioglitazone
preparation
sustained
salt
hours
Prior art date
Application number
MA37034A
Other languages
English (en)
French (fr)
Inventor
Yusuke Murakawa
Yutaka Tanoue
Yumiko Ishii
Kaoru Takenaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47178262&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35717(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA35717B1 publication Critical patent/MA35717B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA37034A 2011-10-21 2014-05-15 Preparation a liberation prolongee MA35717B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011232302 2011-10-21
PCT/JP2012/077662 WO2013058409A1 (en) 2011-10-21 2012-10-19 Sustained-release preparation

Publications (1)

Publication Number Publication Date
MA35717B1 true MA35717B1 (fr) 2014-12-01

Family

ID=47178262

Family Applications (1)

Application Number Title Priority Date Filing Date
MA37034A MA35717B1 (fr) 2011-10-21 2014-05-15 Preparation a liberation prolongee

Country Status (30)

Country Link
US (1) US9907789B2 (cg-RX-API-DMAC7.html)
EP (1) EP2768487B1 (cg-RX-API-DMAC7.html)
JP (1) JP6093762B2 (cg-RX-API-DMAC7.html)
KR (1) KR20140081826A (cg-RX-API-DMAC7.html)
CN (1) CN104039313A (cg-RX-API-DMAC7.html)
AP (1) AP2014007645A0 (cg-RX-API-DMAC7.html)
AR (1) AR088398A1 (cg-RX-API-DMAC7.html)
AU (1) AU2012326976B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014008744A2 (cg-RX-API-DMAC7.html)
CA (1) CA2852417A1 (cg-RX-API-DMAC7.html)
CL (1) CL2014000992A1 (cg-RX-API-DMAC7.html)
CO (1) CO6960544A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140213A (cg-RX-API-DMAC7.html)
DO (1) DOP2014000077A (cg-RX-API-DMAC7.html)
EA (1) EA201490840A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14013328A (cg-RX-API-DMAC7.html)
IL (1) IL232114A0 (cg-RX-API-DMAC7.html)
IN (1) IN2014DN03169A (cg-RX-API-DMAC7.html)
MA (1) MA35717B1 (cg-RX-API-DMAC7.html)
MX (1) MX2014004679A (cg-RX-API-DMAC7.html)
NZ (1) NZ624275A (cg-RX-API-DMAC7.html)
PE (1) PE20141189A1 (cg-RX-API-DMAC7.html)
PH (1) PH12014500856A1 (cg-RX-API-DMAC7.html)
SG (2) SG2014012025A (cg-RX-API-DMAC7.html)
TN (1) TN2014000152A1 (cg-RX-API-DMAC7.html)
TW (1) TW201323018A (cg-RX-API-DMAC7.html)
UA (1) UA113858C2 (cg-RX-API-DMAC7.html)
UY (1) UY34403A (cg-RX-API-DMAC7.html)
WO (1) WO2013058409A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403103B (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014008744A2 (pt) 2011-10-21 2017-04-18 Takeda Pharmaceuticals Co preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer
SG11201401189WA (en) 2012-04-20 2014-09-26 Gilead Sciences Inc Benzothiazol- 6 -yl acetic acid derivatives and their use for treating an hiv infection
US20150141517A1 (en) * 2013-11-15 2015-05-21 Shin-Etsu Chemical Co., Ltd. Granulated composite, rapid release tablet and method for producing same
KR102485766B1 (ko) 2019-12-11 2023-01-09 한국유나이티드제약 주식회사 생체이용률이 향상된 피오글리타존 함유 약학조성물
UY39094A (es) * 2020-02-27 2021-07-30 Hk Inno N Corp Composición farmacéutica que comprende compuesto derivado de bencimidazol
JP2023066053A (ja) * 2021-10-28 2023-05-15 東和薬品株式会社 放出制御医薬組成物
WO2025064867A1 (en) * 2023-09-21 2025-03-27 Yuva Biosciences, Inc. Delivery system for mitochondrial health enhancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810502A (en) 1987-02-27 1989-03-07 Alza Corporation Pseudoephedrine brompheniramine therapy
US4820522A (en) 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
JPH0624991A (ja) 1991-06-20 1994-02-01 Tokyo Tanabe Co Ltd ウルソデスオキシコール酸持続性製剤
JPH0624959A (ja) 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DK0661045T3 (da) 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
JPH06316517A (ja) 1993-02-22 1994-11-15 Grelan Pharmaceut Co Ltd 放出制御製剤
AU8532798A (en) 1997-06-13 1998-12-30 Roland Bodmeier Compounds which delay the release of active substances
US6191154B1 (en) * 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
WO2003013609A1 (fr) 2001-08-03 2003-02-20 Takeda Chemical Industries, Ltd. Medicaments a liberation continue
US9060941B2 (en) 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
EP2604266A1 (en) 2002-09-20 2013-06-19 Andrx Labs Llc Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
IN192749B (cg-RX-API-DMAC7.html) 2002-11-15 2004-05-15 Ranbaxy Lab Ltd
US7442387B2 (en) 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
EP1607088B1 (en) 2003-03-17 2019-02-27 Takeda Pharmaceutical Company Limited Controlled release composition
JP4933033B2 (ja) 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
JP2005015477A (ja) 2003-06-06 2005-01-20 Takeda Chem Ind Ltd 固形製剤
CA2528164A1 (en) 2003-06-06 2004-12-16 Takeda Pharmaceutical Company Limited Solid preparation
US20060003002A1 (en) 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
WO2005099760A1 (ja) 2004-04-14 2005-10-27 Takeda Pharmaceutical Company Limited 固形製剤
MX2007002375A (es) 2004-08-31 2007-04-23 Pfizer Prod Inc Formas de dosificacion de liberacion controlada combinando liberacion inmediata y liberacion sostenida de un farmaco de baja solubilidad.
TW200803851A (en) 2005-09-22 2008-01-16 Sb Pharmco Inc Pharmaceutical composition for improvement of cognitive function
WO2007054976A2 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd. Lipid based controlled release pharmaceutical composition
AU2006328328B2 (en) 2005-12-22 2012-08-30 Takeda Pharmaceutical Company Limited Solid preparation containing an insulin sensitizer
AU2007232836B2 (en) 2006-03-30 2012-12-06 Nippon Zoki Pharmaceutical Co., Ltd. Solid pharmaceutical preparation
JP2009534292A (ja) 2006-04-27 2009-09-24 武田薬品工業株式会社 塩酸ピオグリタゾンを有するアンジオテンシンｉｉ拮抗薬の医薬組成物
DK2120878T3 (da) 2007-02-09 2014-11-03 Alphapharm Pty Ltd Doseringsform indeholdende to aktive farmaceutiske ingredienser i forskellige fysiske former
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
CN101269040A (zh) 2008-05-16 2008-09-24 北京正大绿洲医药科技有限公司 盐酸吡格列酮缓释滴丸及其制备方法
US8445190B2 (en) 2008-09-30 2013-05-21 The Trustees Of The University Of Pennsylvania Method of inhibiting biomaterial-induced procoagulant activity using complement inhibitors
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
WO2011049309A2 (ko) 2009-10-09 2011-04-28 영진약품공업 주식회사 속효성과 지속성을 동시에 갖는 약제학적 조성물
JP2011232302A (ja) 2010-04-30 2011-11-17 Ricoh Elemex Corp 画像検査方法及び画像検査装置
CN101884627B (zh) * 2010-07-07 2012-01-25 青岛黄海制药有限责任公司 盐酸吡格列酮胃内滞留缓释片及其制备方法
KR102171747B1 (ko) * 2011-01-10 2020-11-04 진판델 파마슈티컬스 인코포레이티드 알츠하이머 병 치료를 위한 방법 및 약품
BR112014008744A2 (pt) 2011-10-21 2017-04-18 Takeda Pharmaceuticals Co preparação de libertação prolongada, e, métodos para produzir uma preparação de liberação prolongada, e para prevenir e/ou retardar o início ou suprimir a progressão da doença de alzheimer
KR20160056691A (ko) 2014-11-12 2016-05-20 삼성에스디아이 주식회사 이차전지

Also Published As

Publication number Publication date
AU2012326976A1 (en) 2014-05-29
KR20140081826A (ko) 2014-07-01
SG2014012025A (en) 2014-06-27
EP2768487A1 (en) 2014-08-27
DOP2014000077A (es) 2014-07-15
BR112014008744A2 (pt) 2017-04-18
ECSP14013328A (es) 2014-05-31
ZA201403103B (en) 2015-08-26
UY34403A (es) 2013-05-31
CO6960544A2 (es) 2014-05-30
IN2014DN03169A (cg-RX-API-DMAC7.html) 2015-05-22
WO2013058409A1 (en) 2013-04-25
AR088398A1 (es) 2014-05-28
CN104039313A (zh) 2014-09-10
US20140248362A1 (en) 2014-09-04
AU2012326976B2 (en) 2017-08-17
CR20140213A (es) 2014-06-18
EP2768487B1 (en) 2020-06-03
JP6093762B2 (ja) 2017-03-08
CL2014000992A1 (es) 2014-09-05
SG10201700121YA (en) 2017-03-30
MX2014004679A (es) 2014-08-01
IL232114A0 (en) 2014-06-30
EA201490840A1 (ru) 2014-08-29
PE20141189A1 (es) 2014-09-24
AP2014007645A0 (en) 2014-05-31
PH12014500856A1 (en) 2014-05-19
UA113858C2 (uk) 2017-03-27
CA2852417A1 (en) 2013-04-25
NZ624275A (en) 2016-09-30
TN2014000152A1 (en) 2015-09-30
AU2012326976A2 (en) 2014-06-12
JP2014530802A (ja) 2014-11-20
US9907789B2 (en) 2018-03-06
TW201323018A (zh) 2013-06-16

Similar Documents

Publication Publication Date Title
MA35717B1 (fr) Preparation a liberation prolongee
MX2016000307A (es) Farmaco para el tratamiento de la esteatosis hepatica no alcoholica.
AR116753A1 (es) Proceso de preparación de un derivado de pirazolsulfonilamida
MA42292B1 (fr) Dérivés de sulfamoylarylamide cyclisés et leur utilisation à titre de médicaments pour le traitement de l'hépatite b
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
MA46997B1 (fr) Préparation de complexes solides de cyclodextrine permettant une administration de substance pharmaceutique active ophtalmique
MA41188B1 (fr) Compositions d'insuline à action rapide
MA32903B1 (fr) Inhibiteurs de proteine-kinases
UY32682A (es) "derivados de 1h-imidazo-[4,5-c]-quinolinona"
ECSP099608A (es) Preparacion solida que comprende alogliptina y pioglitazona
MA32306B1 (fr) Derives de quinoleines et de quinoxalines en tant qu'inhibiteurs de proteine tyrosine kinases
MA35749B1 (fr) Dérivés nucléosidiques 4'-azido, 3'-fluoro substitués en tant qu'inhibiteurs de la réplication de l'arn du vhc
MA34819B1 (fr) Dérivés bicyclo[3.2.1]octylamide et leurs utilisations
EP2279244A4 (en) METHOD AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS
AR063538A1 (es) Tratamiento de la enfermedad de parkinson
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
UY32126A (es) Composición farmacéutica sólida
BR112014014877A2 (pt) derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos
MX390332B (es) Una composición farmacéutica que comprende febuxostat e inosina para usarse en el tratamiento de enfermedades en donde existe una deficiencia de atp intracelular.
MX2022009874A (es) Inhibidores heterociclicos de peptidil arginina desiminasa 4 (pad4).
EA201201496A1 (ru) Способ ингибирования интегразы вич, способ улучшения фармакокинетики 6-(3-хлор-2-фторбензил)-1-[(2s)-1-гидрокси-3-метилбутан-2-ил]-7-метокси-4-оксо-1,4-дигидрохинолин-3-карбоновой кислоты (варианты), набор, фармацевтическая композиция (варианты) и антиретровирусный агент (варианты)
FR3056909B1 (fr) Composition comprenant au moins un sel pharmaceutiquement acceptable d'elafibranor soluble en milieux aqueux presentant une absorption intestinale amelioree
MX372773B (es) Ácido (2s, 4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico.
MA46356B1 (fr) Inhibiteurs de bêta-lactamases
EP2722322A4 (en) 1,3-DI-OXO-INDEN DERIVATIVE, PHARMACEUTICALLY ALLOWED SALT AND OPTICAL ISOMER THEREOF, METHOD OF MANUFACTURING THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING THIS DERIVATIVE AS AN ANTIVIRAL ACTIVE SUBSTANCE